STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective
treatment for soft tissue sarcoma.
PURPOSE: Phase I/II trial to study the effectiveness of STI571 in treating patients who have
recurrent or refractory soft tissue sarcoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC